Periodic Reporting for period 1 - Vacc-iNTS (Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa)
Reporting period: 2019-10-01 to 2021-03-31
Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed.
Vacc-iNTS aims to conduct GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis includes serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.
• Technology transfer to a CMO, GMP manufacture and release of the iNTS-GMMA vaccine and placebo lots
• Virtual training on the serology methods based on the procedures applied in preclinical sera analyses.
• Development of the Clinical Trial Document Package for the Phase I clinical study in Europe.
• Development of the protocol for the Phase I Clinical Study Trial in Africa.
• Set up of exploratory immunological analyses.
• Seroepidemiology study protocols and Standard Operating Procedures (SOPs) development as well as community engagement plan (CEP), data management plan (DMP), quality management plan (QMP) and COVID-19 mitigation plan in Malawi, Burkina Faso, Ghana and Kenya.
• Ethical approvals were obtained in Malawi, Burkina Faso, Ghana.
• Manuscript reporting on nontyphoidal Salmonella invasive disease incidence systematic review.
• Manuscript reporting on nontyphoidal Salmonella invasive disease complications and deaths.
• Drafting of manuscript on literature for the Probability of Occurrence model of iNTS disease.
• Initial alignment of objectives and timelines of different work packages relevant for stakeholders meeting and agreement on stakeholders meeting concept note.
• Training of staff in endemic countries
• Effective project coordination and management
• Appointment of Scientific and Ethics advisory Boards
• Consortium Agreement and Data Management Plan
• Effective dissemination and communication
• Plan for Exploitation and Dissemination of project Results
• Project website (www.vacc-ints.eu) creation, update and maintenance
• Twitter handle (@vacc-ints) creation and maintenance
• Community sensitization and dissemination established by all field sites
The objective of the Vacc-iNTS project is to conduct a Phase I study to demonstrate the safety and immunogenicity of the iNTS-GMMA candidate vaccine in healthy European and African adults, and to strengthen a collaborative network of iNTS experts to raise awareness of disease burden and favor vaccine deployment in limited-resource settings.
Vacc-iNTS will undertake essential development of a vaccine for a high burden, truly neglected infectious disease of sSA using new methodology for vaccine production that is simple, low-cost and effective at inducing immune responses. Vacc-iNTS will conduct Phase I clinical trial in Europe and sSA of the iNTS-GMMA vaccine and further advance it for Phase II clinical trials. It is a long overdue intervention for a neglected disease of high importance to Africa. This effort is expected to have a significant impact in reducing disease burden and its socio-economic consequences. Furthermore, Vacc-iNTS will support the clinical development of the GMMA technology, an innovative and affordable vaccine platform suitable to tackle a range of poverty related diseases and significantly contribute to Sustainable Development Goals (SDGs) achievement. Clinical data in the target population from GMMA-based vaccines are indeed essential to define the true potential of this innovative vaccine technology. The Vacc-iNTS project will ultimately increase the number and quality of vaccine candidates for neglected infectious diseases appropriate for implementation and uptake by health systems with limited resources.
The project will significantly contribute to the recommendation, planning, implementation and uptake of the vaccine by low-income countries thanks to its multidisciplinary team of experts, contributing data and evidence at the different stages of this complex process. The partners of Vacc-iNTS will address the downstream constraints for the effective deployment and uptake by limited-resources public health systems of a novel vaccine against iNTS. Understanding the public health value of vaccines for under-recognized diseases of poverty is considered a necessary advocacy information that drives investments on vaccine development, policy, financing and uptake of vaccine in low- and middle-income countries.
Vacc-iNTS will also contribute significantly to capacity building in African by involving scientists from these institutions, providing training as well as exchanging critical information. The knowledge gained from these trainings will be necessary not only to perform the studies in the Vacc-iNTS project, but also for future collaborations.